Home›Stock Screener›Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Share Price Today | Stock Price & Jenburkt Pharmaceuticals Share Screener

JENBURPH Pharmaceuticals & Biotechnology
Live Share Price NSE
₹900.30
▼ -24.15 (-2.61%)
2026-11-19 00:00:00
Live Share Price BSE
₹900.90
▼ -25.90 (-2.79%)
2026-11-19 00:00:00

As of November 19, 2026, the live Jenburkt Pharmaceuticals share price (NSE: JENBURPH) is ₹900.30 on NSE and ₹900.90 on BSE, down 2.61% from the previous close, with shares trading between ₹896.05 and ₹932.95 in today's trading session, and a 52-week range of ₹853.60–₹1,054.40. Track Jenburkt Pharmaceuticals networth to gauge the company's total market size. Use the Jenburkt Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Jenburkt Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹181 and net income of ₹33, with EBITDA of ₹47, an operating margin of 21.0% and a profit margin of 18.2%.

Jenburkt Pharmaceuticals Market Cap - Cr.
JENBURPH P/E Ratio (TTM) 12.90
Jenburkt Pharmaceuticals P/B Ratio 2.07
EPS (TTM) ₹74.50
Dividend Yield 2.15%
Debt to Equity 0.02
JENBURPH 52 Week High ₹1054.40
Jenburkt Pharmaceuticals 52 Week Low ₹853.60
Operating Margin 21.00%
Profit Margin 18.23%
JENBURPH Revenue (TTM) ₹181.00
EBITDA ₹47.00
Net Income ₹33.00
Total Assets ₹226.00
Total Equity ₹197.00

Jenburkt Pharmaceuticals Share Price Chart

Track the current stock price of Jenburkt Pharmaceuticals with an interactive chart. Analyse JENBURPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Jenburkt Pharmaceuticals stock quote in one place.

The quote of ₹900.30 sits between the 52-week low of ₹853.60 and the 52-week high of ₹1,054.40, and the latest session moved -2.61% from the previous close.

Jenburkt Pharmaceuticals Company Profile - Fundamental Screener

Screen Jenburkt Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JENBURPH shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE354A01013.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE354A01013

Jenburkt Pharmaceuticals Balance Sheet Screener

Screen JENBURPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹226, up from ₹196 in 2025.

Latest statistics put total assets at ₹226 and shareholder funds at ₹197, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 226 196 165 142 143 121 104 103 78 76
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 20 15 10 10 11 11 12 10 10 11

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 6 6 4 4 4 5 5 3 3 4
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 197 172 145 122 117 99 80 78 61 54
Share Capital 4 4 4 4 5 5 5 5 5 5
Reserves & Surplus 193 167 141 118 113 94 75 73 57 50

Jenburkt Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Jenburkt Pharmaceuticals income statement and profit fundamentals. Analyze JENBURPH quarterly results. Jenburkt Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹181 and net profit was ₹33, equal to earnings per unit of ₹74.50, at an operating margin of 21%.

In that period expenses were ₹135, interest cost ₹0 and tax ₹11. The next period listed, 2026-March, shows revenue of ₹179 and net profit of ₹35.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 181 179 158 147 142 129 114 123 126 118 106 96 87
Expenses 135 125 111 109 106 97 90 99 98 91 84 77 70

Operating Costs and Margins

EBITDA 47 54 47 38 36 32 24 24 28 27 23 19 17
Operating Profit % 21.00% 26.00% 27.00% 23.00% 22.00% 22.00% 18.00% 17.00% 20.00% 21.00% 19.00% 18.00% 18.00%
Depreciation 3 3 3 2 2 2 2 2 1 2 2 2 3
Interest 0 1 1 0 0 0 1 1 0 0 0 0 0

Profit and Earnings

Profit Before Tax 43 47 44 35 33 30 22 21 27 25 21 17 14
Tax 11 12 12 9 8 8 5 6 7 8 7 6 5
Net Profit 33 35 32 26 25 22 17 15 20 17 14 11 10
EPS 74.50 78.71 72.65 58.86 53.90 48.58 35.96 32.40 43.14 37.50 29.05 23.18 20.75

Jenburkt Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen JENBURPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹27, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹20 and financing activities used ₹9.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 27 28 8 17 9 20 15 13 16 10
Investing Activities -20 -17 -1 3 -1 -19 -3 -11 1 -10

Financing and Net Cash

Financing Activities -9 -8 -7 -21 -6 -1 -11 -2 -18 1
Net Cash Flow -2 3 1 -1 3 0 1 0 -1 1

Jenburkt Pharmaceuticals Shareholding Pattern Screener

See Jenburkt Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Jenburkt Pharmaceuticals promoter holding and ownership changes for JENBURPH on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 46.64%, foreign institutions 0.00%, domestic institutions 0.12% and the public 41.03%, spread across 6,999 shareholders.

The shareholder count was 6,999 in 2026-Mar, compared with 7,103 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 46.64% 46.62% 46.62% 46.68% 46.67% 46.66% 46.65% 47.23%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.12% 0.12% 0.03% 0.12% 0.12% 0.12% 0.12% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 41.03% 41.05% 34.39% 43.55% 43.32% 43.26% 43.13% 42.65%
Other Holding 12.21% 12.21% 18.96% 9.66% 9.89% 9.97% 10.10% 10.11%
Shareholder Count 6,999 7,103 7,351 6,987 6,712 6,855 7,163 6,316

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Jenburkt Pharmaceuticals. Jenburkt Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹20.70 per unit for 2026-March, a yield of 2.15%, compared with ₹18.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹20.70, ₹18.00 and ₹15.30 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹20.70 2.15%
2025-March ₹18.00 1.88%
2024-March ₹15.30 1.51%
2023-March ₹14.40 2.09%
2022-March ₹12.00 1.82%
2021-March ₹10.20 1.80%
2020-March ₹8.10 2.03%
2019-March ₹10.20 3.21%
2018-March ₹9.00 1.78%
2017-March ₹8.10 1.32%

Jenburkt Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Jenburkt Pharmaceuticals stock. Check JENBURPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Jenburkt Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Jenburkt Pharmaceuticals Market Events Screener - Corporate Actions

Get Jenburkt Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Jenburkt Pharmaceuticals stock events that may affect JENBURPH share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.

It is followed by Annual General Meeting dated September 4, 2026 and Dividend dated August 28, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-03 2026-11-03 Quarterly Result Announcement NA -1.12%
2026-09-04 2026-09-04 Annual General Meeting NA -0.21%
2026-08-28 2026-08-28 Dividend ₹ 20.70 /share -0.90%
2026-08-06 2026-08-06 Quarterly Result Announcement NA 9.31%
2026-05-05 2026-05-05 Quarterly Result Announcement NA -1.25%
2026-02-03 2026-02-03 Quarterly Result Announcement NA -2.87%
2025-10-28 2025-10-28 Quarterly Result Announcement NA 0.91%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -9.73%
2025-07-18 2025-07-18 Annual General Meeting NA 18.69%
2025-07-11 2025-07-11 Dividend ₹ 18.00 /share 25.87%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 9.69%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -6.60%
2024-11-05 2024-11-05 Quarterly Result Announcement NA 7.15%
2024-07-30 2024-07-30 Annual General Meeting NA 16.63%
2024-07-23 2024-07-24 Dividend ₹ 15.30 /share 8.04%

Jenburkt Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen JENBURPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.70 11,067 13.95% 2,568 78.53
Laurus Labs 130,972 98.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 41.70 35,059 3.90% 4,158 70.24
Cipla 112,438 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.40 14,636 14.85% 1,938 65.43
Glenmark Pharmaceuticals 74,507 51.40 17,443 29.83% 1,362 69.89
Biocon 59,329 175.50 17,270 4.85% 369 53.86
Abbott 56,183 34.00 7,217 7.97% 1,552 52.33

Jenburkt Pharmaceuticals Company Announcements - News & Reports Screener

Screen JENBURPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 4, 2026.

The next most recent announcements are dated November 4, 2026 and November 3, 2026.

Date Update Actions
2026-11-04 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-03 Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 03Rd November 2026. -
2026-11-03 Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 -
2026-10-29 Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026. -
2026-10-12 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-22 Intimation Regarding Admission Of Equity Shares Of The Company Under Permitted To Trade Category On National Stock Exchange Of India Limited. -
2026-09-22 Closure of Trading Window -
2026-09-18 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-04 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-09-04 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-04 Proceedings Of The 41St Annual General Meeting Of The Company Held On Friday 04Th September 2026. -
2026-09-04 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-04 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-06 Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2026. -
2026-08-06 Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 06Th August 2026. -
2026-08-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-03 Notice Of The 41St Annual General Meeting Of The Company Schedule To Be Held On Friday 04Th September 2026 Through VC/OAVM. -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹900.30, within a 52-week range of ₹853.60 to ₹1,054.40. The P/E ratio is 12.90 and the P/B ratio is 2.07, with earnings per unit of ₹74.50. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.